Lantern Pharma Inc.
LTRN
$3.59
-$0.03-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.09M | 5.77M | 5.62M | 5.73M | 5.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.22M | 21.20M | 19.54M | 19.32M | 17.88M |
| Operating Income | -22.22M | -21.20M | -19.54M | -19.32M | -17.88M |
| Income Before Tax | -20.78M | -19.09M | -17.75M | -17.53M | -15.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.78 | -19.09 | -17.75 | -17.53 | -15.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.78M | -19.09M | -17.75M | -17.53M | -15.96M |
| EBIT | -22.22M | -21.20M | -19.54M | -19.32M | -17.88M |
| EBITDA | -22.20M | -21.18M | -19.53M | -19.31M | -17.86M |
| EPS Basic | -1.93 | -1.78 | -1.65 | -1.62 | -1.47 |
| Normalized Basic EPS | -1.19 | -1.11 | -1.03 | -1.02 | -0.93 |
| EPS Diluted | -1.93 | -1.78 | -1.65 | -1.62 | -1.47 |
| Normalized Diluted EPS | -1.19 | -1.11 | -1.03 | -1.02 | -0.93 |
| Average Basic Shares Outstanding | 43.15M | 43.00M | 43.09M | 43.19M | 43.30M |
| Average Diluted Shares Outstanding | 43.15M | 43.00M | 43.09M | 43.19M | 43.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |